Clinical Trial Update: Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating eflornithine with or without triamcinolone for preventing nonmelanoma skin cancer in patients with actinic keratosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Non-melanoma Skin Cancer

Drugs mentioned

• Eflornithine (eflornithine)
• Triamcinolone (triamcinolone)

Snippet

Sponsor: University of Arizona | Conditions: Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition | Phase 2 | Status: COMPLETED